Login to Your Account



AMRN Down 61%

Amarin Stock Drops on FDA’s Lipid Biomarker Sea Change

By Catherine Shaffer
Staff Writer

Friday, October 18, 2013
Shares in Amarin Corp. plc fell 61 percent Thursday following Wednesday’s surprise vote by the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommending against approval of the firm’s marketed fish oil-derived lipid-lowering drug Vascepa in a supplemental indication.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription